Arrowhead Reports Fiscal 2010 Second Quarter
May 13, 2010 07:03 AM Eastern Daylight Time
PASADENA, Calif.--(EON: Enhanced Online News)--Arrowhead Research Corporation (NASDAQ:
ARWR) today announced financial results for its fiscal 2010 second quarter ended March 31, 2010.
“During the fiscal 2010 second quarter, Arrowhead took a remarkable step forward,” said Christopher Anzalone,
Arrowhead’s Chief Executive Officer. “In March, our majority-owned subsidiary, Calando Pharmaceuticals,
announced data that demonstrated first proof of systemic delivery of siRNA and gene silencing via RNAi in humans.
This is an exciting milestone both for our Company and the broader industry. It had long been our goal to be the first
company to demonstrate systemic delivery, and we have now achieved that goal. Positive industry and market
reception has been encouraging and provides further validation and recognition of the potential value of this
“We also continue to make progress with Unidym, following the prior achievement of our goal of initial market entry
in calendar 2009 with our first sale in December of our transparent conductive film product in the touch panel
market. Since then, we have continued to work with manufacturers to integrate our product into their devices and
make connections in key Asian geographies as well as with potential U.S. partners to increase our market traction.
“As we look to add to our portfolio of nanomedicine subsidiaries, we also welcomed two new members to our
Scientific Advisory Board: Nobel laureate Dr. Leland Hartwell and former commissioner of the FDA, Dr. Andrew
von Eschenbach,” continued Dr. Anzalone. “These esteemed gentlemen, along with the preeminent leaders in
nanotechnology already on the Board, are expected to play a key role in refining Arrowhead’s strategy as we
increase our focus on the opportunities to develop medical applications based on the advances in materials
engineering at the nanoscale.”